SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) has revealed that fresh and updated data from its lentiviral vector (LVV) gene addition programs targeting patients suffering from
sickle cell disease and
beta-thalassemia will be showcased at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. This notable event is scheduled to run from December 7-10, 2024, at the San Diego Convention Center as well as online.
Richard Colvin, M.D., Ph.D., the chief medical officer at bluebird bio, emphasized the significant long-term potential of bluebird’s gene therapies. He remarked that the company's programs are among the most thoroughly examined in the gene therapy sector, with follow-up periods extending up to a decade for patients with
transfusion-dependent beta-thalassemia and almost ten years for those with sickle cell disease. Dr. Colvin expressed particular enthusiasm for the first targeted sub-analysis of
lovo-cel’s clinical impact on patients with a history of
stroke, which stands out among gene therapies for sickle cell disease.
bluebird bio will present updated follow-up data and analyses on lovotibeglogene autotemcel (lovo-cel) from the HGB-206 and HGB-210 studies. The findings highlight consistent clinical outcomes as early as six months post-infusion and the sustained benefits of lovo-cel. An integrated analysis focusing on sickle cell disease patients with a history of stroke will also be presented. This includes data from both overt and silent stroke cases across the HGB-206 Group A and Group C studies and the HGB-210 study, demonstrating clinical benefits in these patients and consistent outcomes within the broader lovo-cel-treated population. The safety profile of the lovo-cel treatment reflects the known effects of sickle cell disease and myeloablative conditioning, with similar safety across different age groups.
Additionally, bluebird bio will share updated long-term analyses regarding the efficacy, safety, and health-related quality of life data of
betibeglogene autotemcel (beti-cel) in patients with transfusion-dependent beta-thalassemia (TDT). Data from long-term follow-up studies, extending up to ten years, show that patients with TDT achieved durable transfusion independence and normal or near-normal hemoglobin levels, regardless of their genotype and age, while maintaining a favorable long-term safety profile.
The presentations include:
1. Oral Presentation [#511]: An Update on Lovotibeglogene Autotemcel (lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-cel. Presenter: Dr. Stacey Rifkin-Zenenberg. Date/Time: Sunday, December 8, 2024, 9:30 a.m. – 11:00 a.m. PT.
2. Poster Presentation [#3576]: Participants with a History of Stroke in Lovotibeglogene Autotemcel (lovo-cel) Clinical Trials. Presenter: Dr. Jen Jaroscak. Date/Time: Sunday, December 8, 2024, 6:00 p.m. – 8:00 p.m. PT.
3. Poster Presentation [#2194]: Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy results in durable
Hemoglobin A (HbA) Production with up to 10 Years of Follow-Up in Participants with Transfusion-Dependent β-Thalassemia. Presenter: Dr. Alexis A Thompson. Date/Time: Saturday, December 7, 2024, 5:30 p.m. – 7:30 p.m. PT.
Lovo-cel received U.S. Food and Drug Administration (FDA) approval in December 2023 and is commercially available in the United States as LYFGENIA. Similarly, beti-cel was approved by the FDA in August 2022 and is available in the U.S. under the name ZYNTEGLO.
About LYFGENIA™ (lovotibeglogene autotemcel):
LYFGENIA is a one-time ex-vivo lentiviral vector gene therapy approved for treating patients aged 12 and older with sickle cell disease and a history of vaso-occlusive events (VOEs). It functions by adding a functional β-globin gene to the patients’ hematopoietic stem cells (HSCs), enabling the production of adult hemoglobin with anti-sickling properties (HbAT87Q), which can reduce VOEs. The safety and efficacy of LYFGENIA are being evaluated in the ongoing Phase 3 HGB-210 study, with long-term follow-up studies also underway.
About ZYNTEGLO™ (betibeglogene autotemcel):
ZYNTEGLO is a pioneering one-time ex-vivo LVV gene therapy for adults and pediatric patients requiring regular red blood cell transfusions due to beta-thalassemia. It works by inserting functional copies of a modified β-globin gene into a patient’s stem cells, subsequently producing modified functional adult hemoglobin (HbAT87Q). This can potentially elevate hemoglobin levels to normal or near-normal, eliminating the need for regular transfusions.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
